0377 Oslo, Norway
Tel +47 23 25 40 03
Pål Kristian Selbo
Victoria Tudor Edwards
The strategy of PCI Biotech Holding ASA (PCI Biotech) is to commercialise a patented photochemical drug delivery technology for use in therapeutic treatment.
The company was established in 2000 as a subsidiary of the Norwegian pharmaceutical company Photocure ASA. PCI Biotech has been listed on Oslo Axess since June 2008 following a demerger from Photocure ASA.
PCI Biotech receives substantial public funding from the Norwegian Research Council and from the EU.
Photochemical internalisation is a drug delivery technology for targeted delivery of macromolecules and other membrane-impermeable drugs.
PCI can be used within many areas, including:
• gene therapy
• protein therapy
• oligonucleotide therapy
The PCI technology has great advantages as it may:
• enhance and target drug delivery
• make macromolecule delivery more efficient
• make possible the therapeutic use of molecules that it has hitherto been impossible to use, due to e.g. too low delivery efficiency or too high toxicity in non-target tissues.